Trial · NCT06598306
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Dose-limiting toxicities (DLTs) | Up to day 21 | |
| Primary | Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Up to approximately 24 months | |
| Primary | Number of Participants with Changes in Vital Signs | Up to approximately 24 months | |
| Primary | Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests | Up to approximately 24 months | |
| Secondary | Maximum Serum Concentration (Cmax) of Tarlatamab | Up to approximately 12 months | |
| Secondary | Serum Concentration Prior to Dosing (Ctrough) of Tarlatamab | Up to approximately 12 months | |
| Secondary | Time to Cmax (Tmax) of Tarlatamab | Up to approximately 12 months | |
| Secondary | Area Under the Concentration-time Curve (AUC) of Tarlatamab | Up to approximately 12 months | |
| Secondary | Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | Up to approximately 24 months | |
| Secondary | Duration of Response (DOR) per RECIST 1.1 | Up to approximately 24 months | |
| Secondary | Time to Response (TTR) per RECIST 1.1 | Up to approximately 24 months | |
| Secondary | Progression-free Survival (PFS) per RECIST 1.1 | Up to approximately 24 months | |
| Secondary | Time to Progression per RECIST 1.1 | Up to approximately 24 months | |
| Secondary | Time to Subsequent Therapy | Up to approximately 24 months | |
| Secondary | Overall Survival (OS) | Up to approximately 24 months | |
| Secondary | Number of Participants with Anti-tarlatamab Antibody Formation | Up to approximately 24 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06598306/registered